535 related articles for article (PubMed ID: 18199989)
1. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
2. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
[TBL] [Abstract][Full Text] [Related]
3. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
[TBL] [Abstract][Full Text] [Related]
4. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia.
Horacek JM; Tichy M; Jebavy L; Pudil R; Ulrychova M; Maly J
Exp Oncol; 2008 Jun; 30(2):157-9. PubMed ID: 18566582
[TBL] [Abstract][Full Text] [Related]
5. [Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients].
Qin J; Zhang PH; Qian XY; Kang SJ; Luo RC; Wang YG
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):930-2. PubMed ID: 18583230
[TBL] [Abstract][Full Text] [Related]
6. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-based risk assessment model in acute pulmonary embolism.
Kostrubiec M; Pruszczyk P; Bochowicz A; Pacho R; Szulc M; Kaczynska A; Styczynski G; Kuch-Wocial A; Abramczyk P; Bartoszewicz Z; Berent H; Kuczynska K
Eur Heart J; 2005 Oct; 26(20):2166-72. PubMed ID: 15911566
[TBL] [Abstract][Full Text] [Related]
8. Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise.
Scharhag J; Herrmann M; Urhausen A; Haschke M; Herrmann W; Kindermann W
Am Heart J; 2005 Dec; 150(6):1128-34. PubMed ID: 16338248
[TBL] [Abstract][Full Text] [Related]
9. N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratification in patients admitted for cardiac emergency.
Yamashita T; Seino Y; Ogawa A; Ogata K; Fukushima M; Tanaka K; Mizuno K
J Cardiol; 2010 May; 55(3):377-83. PubMed ID: 20350516
[TBL] [Abstract][Full Text] [Related]
10. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
11. Circulating N-terminal pro-brain natriuretic peptide and cardiac troponin T in chronic dialysis patients.
Leowattana W; Ong-Ajyooth L; Taruangsri P; Pokum S
J Med Assoc Thai; 2003 May; 86 Suppl 1():S52-8. PubMed ID: 12866769
[TBL] [Abstract][Full Text] [Related]
12. Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation.
Horacek JM; Tichy M; Pudil R; Jebavy L; Zak P; Ulrychova M; Slovacek L; Maly J
Neoplasma; 2008; 55(6):532-7. PubMed ID: 18999883
[TBL] [Abstract][Full Text] [Related]
13. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
[TBL] [Abstract][Full Text] [Related]
14. Analysis of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes.
Coppola G; Corrado E; Mulè MC; Augugliaro S; Cucchiara A; Novo G; Amoroso G; Assennato P; Hoffmann E; Vitale F; Novo S
Coron Artery Dis; 2009 May; 20(3):225-9. PubMed ID: 19387249
[TBL] [Abstract][Full Text] [Related]
15. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease.
Chrysochou C; Manzoor S; Wright J; Roberts SA; Wood G; McDowell G; Kalra PA
Kidney Blood Press Res; 2009; 32(5):373-9. PubMed ID: 19887825
[TBL] [Abstract][Full Text] [Related]
16. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Heeschen C; Hamm CW; Mitrovic V; Lantelme NH; White HD;
Circulation; 2004 Nov; 110(20):3206-12. PubMed ID: 15533869
[TBL] [Abstract][Full Text] [Related]
17. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature.
Mavinkurve-Groothuis AM; Kapusta L; Nir A; Groot-Loonen J
Pediatr Hematol Oncol; 2008 Sep; 25(7):655-64. PubMed ID: 18850478
[TBL] [Abstract][Full Text] [Related]
18. A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes.
Cameron SJ; Sokoll LJ; Laterza OF; Shah S; Green GB
Clin Chim Acta; 2007 Feb; 376(1-2):168-73. PubMed ID: 17011538
[TBL] [Abstract][Full Text] [Related]
19. Cardiac biomarkers and survival in haemodialysis patients.
Sommerer C; Beimler J; Schwenger V; Heckele N; Katus HA; Giannitsis E; Zeier M
Eur J Clin Invest; 2007 May; 37(5):350-6. PubMed ID: 17461980
[TBL] [Abstract][Full Text] [Related]
20. [Personal experience with determination of NT-proBNP in clinical practice].
Stejskal D; Oral I; Lacnák B; Juráková R; Horalík D; Adamovská S; Prosková J; Hrabovská I; Ozanová G
Vnitr Lek; 2003 Feb; 49(2):121-6. PubMed ID: 12728579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
